Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EOLS NASDAQ:EVLO NASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$6.28+12.5%$4.68$3.86▼$12.15$407.02M1.281.19 million shs3.01 million shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.00$5K0.612,879 shsN/AMNOVMediciNova$1.43+2.1%$1.42$1.17▼$1.96$70.39M0.6360,940 shs6,519 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus0.00%+2.11%+32.26%+13.40%-55.88%EVLOEvelo Biosciences0.00%+150.00%+150.00%+25.00%-16.67%MNOVMediciNova0.00%+2.19%-2.78%-14.63%-7.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$6.28+12.5%$4.68$3.86▼$12.15$407.02M1.281.19 million shs3.01 million shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.00$5K0.612,879 shsN/AMNOVMediciNova$1.43+2.1%$1.42$1.17▼$1.96$70.39M0.6360,940 shs6,519 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus0.00%+2.11%+32.26%+13.40%-55.88%EVLOEvelo Biosciences0.00%+150.00%+150.00%+25.00%-16.67%MNOVMediciNova0.00%+2.19%-2.78%-14.63%-7.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOLSEvolus 2.50Moderate Buy$16.00150.20% UpsideEVLOEvelo Biosciences 0.00N/AN/AN/AMNOVMediciNova 2.86Moderate Buy$7.50428.17% UpsideCurrent Analyst Ratings BreakdownLatest MNOV, EVLO, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026MNOVMediciNova D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/24/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)3/27/2026MNOVMediciNova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/23/2026MNOVMediciNova Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.003/17/2026MNOVMediciNova Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/16/2026MNOVMediciNova HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.003/4/2026EOLSEvolus BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOLSEvolus$297.18M1.40N/AN/A($0.36) per share-17.76EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AMNOVMediciNova$410K170.47N/AN/A$0.85 per share1.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOLSEvolus-$51.64M-$0.81N/A127.90N/A-17.38%N/A-21.57%N/AEVLOEvelo Biosciences-$114.53M-$8.81N/AN/AN/AN/AN/AN/A5/14/2026 (Estimated)MNOVMediciNova-$12M-$0.24N/AN/AN/AN/A-26.32%-24.55%5/13/2026 (Estimated)Latest MNOV, EVLO, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026N/AEVLOEvelo Biosciences-$10.40N/AN/AN/AN/AN/A5/13/2026N/AMNOVMediciNova-$0.06N/AN/AN/A$0.13 millionN/A5/4/2026Q1 2026EOLSEvolus-$0.14-$0.16-$0.02-$0.16$72.52 million$73.14 million3/3/2026Q4 2025EOLSEvolus$0.09$0.0020-$0.0880N/A$89.58 million$90.30 million2/20/2026Q4 2025MNOVMediciNova-$0.0950-$0.05+$0.0450-$0.05N/A$0.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEOLSEvolusN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOLSEvolusN/A1.901.54EVLOEvelo BiosciencesN/AN/AN/AMNOVMediciNovaN/A8.168.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOLSEvolus90.69%EVLOEvelo Biosciences0.31%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipEOLSEvolus5.90%EVLOEvelo Biosciences1.02%MNOVMediciNova13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOLSEvolus17065.06 million61.09 millionOptionableEVLOEvelo Biosciences12018.84 million18.79 millionNo DataMNOVMediciNova1049.22 million42.53 millionOptionableMNOV, EVLO, and EOLS HeadlinesRecent News About These CompaniesD. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV)May 4 at 9:35 AM | marketbeat.comMediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short InterestMay 1, 2026 | marketbeat.comMediciNova Announces New Insights on Brain Metastasis Vulnerability and Potential Therapeutic Strategies from CNIO StudyApril 27, 2026 | quiverquant.comQNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationApril 27, 2026 | globenewswire.comMediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from BrokeragesApril 17, 2026 | marketbeat.comMediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving Average - Here's WhyApril 16, 2026 | marketbeat.comMediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average - Here's What HappenedApril 8, 2026 | marketbeat.comHC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendationMarch 17, 2026 | msn.comMediciNova to Participate at the 38th Annual ROTH ConferenceMarch 16, 2026 | globenewswire.comMediciNova: Q4 Earnings SnapshotFebruary 20, 2026 | wtop.comWMediciNova (MNOV) price target increased by 28.57% to 9.18February 4, 2026 | msn.comMediciNova Reports 100 Patient Enrollment in SEANOBI Study for MN-166 (Ibudilast) in ALS TreatmentJanuary 29, 2026 | quiverquant.comQMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsJanuary 29, 2026 | globenewswire.comMediciNova, Inc.: 2026 New Year's Greetings from the CEOJanuary 7, 2026 | finanznachrichten.de2026 New Year’s Greetings from the CEOJanuary 7, 2026 | finance.yahoo.comMediciNova issues letter to shareholdersJanuary 7, 2026 | msn.com2026 New Year's Greetings from the CEOJanuary 6, 2026 | globenewswire.comMediciNova Establishes Flexible At-The-Market Equity ProgramDecember 30, 2025 | tipranks.comMediciNova completes patient enrollment in neuropathy trial of MN-166December 18, 2025 | msn.comMediciNova, Inc.: MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral NeuropathyDecember 18, 2025 | finanznachrichten.deMediciNova, Inc. Completes Patient Enrollment in Phase 2 OXTOX Study for MN-166 in Metastatic Colorectal Cancer PatientsDecember 18, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNOV, EVLO, and EOLS Company DescriptionsEvolus NASDAQ:EOLS$6.28 +0.70 (+12.46%) As of 02:46 PM Eastern This is a fair market value price provided by Massive. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Evelo Biosciences NASDAQ:EVLO$0.0003 0.00 (0.00%) As of 05/1/2026Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.MediciNova NASDAQ:MNOV$1.43 +0.03 (+2.14%) As of 02:41 PM Eastern This is a fair market value price provided by Massive. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas onsemi Stock Dips After Earnings: Why the Dip Is Buyable Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom Atomic Dividends: Big Tech's New Energy Bet Monolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Leading Insider Sales: April Activity Ramps in These Stocks The New Fed Chair Trade: Who Wins When Warsh Takes the Helm? A Prada Payday: Is AMC Back in Style? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
